PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Fumagillin→

Fumagillin PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
23110-15-8
Molecular formula
C26H34O7
Molecular weight
458.55 g/mol
Drug class
Antimicrosporidial antibioticmethionine aminopeptidase-2 (MetAP2) inhibitor
Mechanism of action
Inhibits methionine aminopeptidase 2, an enzyme required for protein maturation and microsporidial proliferation. MetAP2 inhibition also accounts for antiangiogenic activity observed in other experimental settings.
Indications / reported uses
  • Treatment of intestinal microsporidiosis caused by Enterocytozoon bieneusi in selected immunocompromised patients under specialist guidance.
  • Topical compounded fumagillin has been used for ocular microsporidial infection; systemic and topical availability is limited and jurisdiction-specific.

Sources: https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-opportunistic-infections/microsporidiosis · https://www.nejm.org/doi/full/10.1056/NEJMoa012924 · FDA product information

View request basketPrefer email? info@toxwriter.com
PDE / ADE derivationOEL derivationOEB / OHC banding
Assessment scope

PDE/ADE and OEL/OEB assessment

ToxWriter provides project-specific support for Fumagillin PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Fumagillin Permitted Daily Exposure (PDE) report (the Fumagillin PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Fumagillin Occupational Exposure Limit (OEL) report (the Fumagillin OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.